Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
admin 17th May 2017 Uncategorised 0One of AbbVie’s Humira patents bit the dust late Tuesday, marking a win for biosimilars makers. But they still have a long way to go before they’ll really be able to celebrate, analysts cautioned.
More: Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Source: fierce